drugset / Trial / NCT00002371

The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

NCT00002371

Phase 3 Completed 80 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the magnitude and durability of the reduction in plasma HIV RNA in the two treatment groups over the first 12 weeks of treatment. To determine the safety of each of the two treatment groups.

Timeline

Start
1996-06
Primary completion
1997-12
Completion
1997-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Stavudine Other / unclassified
Subject Zidovudine Small molecule
Background INDINAVIR ANHYDROUS Other / unclassified
Background Lamivudine Other / unclassified